Literature DB >> 14504135

Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells.

Mary E Gerritsen1, James E Tomlinson, Constance Zlot, Michael Ziman, Stuart Hwang.   

Abstract

Hepatocyte growth factor (HGF) and vascular endothelial cell growth factor (VEGF) are two potent endothelial mitogens with demonstrated angiogenic activities in animal models of therapeutic angiogenesis. Several recent studies suggest that these growth factors may act synergistically, although the mechanism of this interaction is not understood. Changes in the gene expression profile of human umbilical vein endothelial cells treated with HGF, VEGF or the combination of the two were analyzed with high-density oligonucleotide arrays, representing approximately 22000 genes. Notably, the genes significantly up- and downregulated by VEGF versus HGF exhibited very little overlap, indicating distinct signal transduction pathways. The combination of HGF and VEGF markedly increased the number of significantly up- and downregulated genes. At 4 h, the combination of the two growth factors induced a number of chemokine and cytokines and their receptors (IL-8, IL-6, IL-11, CCR6, CXCR1,CXC1 and IL17RC), numerous genes involved in growth factor signal transduction (egr-1, fosB, grb10, grb14,MAP2K3,MAP3K8, MAPKAP2,MPK3, DUSP4 and DUSP6), as well as a number of other growth factors (PDGFA, BMP2, Hb-EGF, FGF16, heuregulin beta 1, c-kit ligand, angiopoietin 2 and angiopoietin 4 and VEGFC). In addition, the VEGF receptors neuropilin-1 and flt-1 were also upregulated. At 24 h, a clear 'cell cycle' signature is noted, with the upregulated expression of various cell cycle control proteins and gene involved in the regulation of mitosis and mitotic spindle assembly. The receptor for HGF, c-met, is also upregulated. These data are consistent with the hypothesis that the combination of HGF and VEGF results in the cooperative upregulation of a number of different molecular pathways leading to a more robust proliferative response, that is, growth factor(s), receptors, molecules involved in growth factor signal transduction, as well as, at later time points, upregulation of the necessary cellular proteins required for cells to escape cell cycle arrest and enter the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504135      PMCID: PMC1574080          DOI: 10.1038/sj.bjp.0705494

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  51 in total

1.  Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells.

Authors:  W G Jiang; T A Martin; K Matsumoto; T Nakamura; R E Mansel
Journal:  J Cell Physiol       Date:  1999-11       Impact factor: 6.384

2.  Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles.

Authors:  C J Roberts; B Nelson; M J Marton; R Stoughton; M R Meyer; H A Bennett; Y D He; H Dai; W L Walker; T R Hughes; M Tyers; C Boone; S H Friend
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

3.  Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial.

Authors:  D F Lazarous; E F Unger; S E Epstein; A Stine; J L Arevalo; E Y Chew; A A Quyyumi
Journal:  J Am Coll Cardiol       Date:  2000-10       Impact factor: 24.094

4.  bFGF increases collateral blood flow in aged rats with femoral artery ligation.

Authors:  H T Yang; Y Feng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-01       Impact factor: 4.733

5.  Gene expression profiling in an in vitro model of angiogenesis.

Authors:  J Kahn; F Mehraban; G Ingle; X Xin; J E Bryant; G Vehar; J Schoenfeld; C J Grimaldi; F Peale; A Draksharapu; D A Lewin; M E Gerritsen
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 6.  The biology of stem cell factor and its receptor C-kit.

Authors:  L K Ashman
Journal:  Int J Biochem Cell Biol       Date:  1999-10       Impact factor: 5.085

7.  Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells.

Authors:  S Hayashi; R Morishita; S Nakamura; K Yamamoto; A Moriguchi; T Nagano; M Taiji; H Noguchi; K Matsumoto; T Nakamura; J Higaki; T Ogihara
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

8.  Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.

Authors:  I Kim; J H Kim; S O Moon; H J Kwak; N G Kim; G Y Koh
Journal:  Oncogene       Date:  2000-09-14       Impact factor: 9.867

Review 9.  The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor.

Authors:  H H Nandurkar; L Robb; C G Begley
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

Review 10.  The role of recombinant interleukin 11 in megakaryocytopoiesis.

Authors:  K J Turner; S Neben; N Weich; R G Schaub; S J Goldman
Journal:  Stem Cells       Date:  1996       Impact factor: 6.277

View more
  44 in total

1.  Quantification and cell-to-cell variation of vascular endothelial growth factor receptors.

Authors:  P I Imoukhuede; Aleksander S Popel
Journal:  Exp Cell Res       Date:  2010-12-23       Impact factor: 3.905

2.  Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization.

Authors:  Alexander V Ljubimov; Sergio Caballero; Annette M Aoki; Lorenzo A Pinna; Maria B Grant; Raquel Castellon
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-12       Impact factor: 4.799

3.  Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.

Authors:  Chao-Nan Qian; Kyle A Furge; Jared Knol; Dan Huang; Jindong Chen; Karl J Dykema; Eric J Kort; Aaron Massie; Sok Kean Khoo; Kristin Vanden Beldt; James H Resau; John Anema; Richard J Kahnoski; Hans Morreau; Philippe Camparo; Eva Comperat; Mathilde Sibony; Yves Denoux; Vincent Molinie; Annick Vieillefond; Charis Eng; Bart O Williams; Bin Tean Teh
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

4.  Dual delivery of vascular endothelial growth factor and hepatocyte growth factor coacervate displays strong angiogenic effects.

Authors:  Hassan K Awada; Noah R Johnson; Yadong Wang
Journal:  Macromol Biosci       Date:  2014-01-23       Impact factor: 4.979

5.  Signaling and functions of angiopoietin-1 in vascular protection.

Authors:  Nicholas P J Brindle; Pipsa Saharinen; Kari Alitalo
Journal:  Circ Res       Date:  2006-04-28       Impact factor: 17.367

6.  A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Authors:  Geoffrey I Shapiro; Stewart McCallum; Laurel M Adams; Laurie Sherman; Steve Weller; Suzanne Swann; Harold Keer; Dale Miles; Thomas Müller; Patricia Lorusso
Journal:  Invest New Drugs       Date:  2012-10-06       Impact factor: 3.850

7.  Hepatocyte growth factor inhibits VEGF-forkhead-dependent gene expression in endothelial cells.

Authors:  Md Ruhul Abid; Robert J Nadeau; Katherine C Spokes; Takashi Minami; Dan Li; Shou-Ching Shih; William C Aird
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-11       Impact factor: 8.311

8.  Endocan-expressing microvessel density as a prognostic factor for survival in human gastric cancer.

Authors:  Yuan Chang; Wei Niu; Pei-Long Lian; Xian-Qiang Wang; Zhi-Xin Meng; Yi Liu; Rui Zhao
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

9.  Successful use of platelet-rich plasma for chronic plantar fasciitis.

Authors:  Martin J O'Malley; J Turner Vosseller; Yang Gu
Journal:  HSS J       Date:  2013-05-18

Review 10.  Platelet-rich therapies in the treatment of orthopaedic sport injuries.

Authors:  Mikel Sánchez; Eduardo Anitua; Gorka Orive; Iñigo Mujika; Isabel Andia
Journal:  Sports Med       Date:  2009       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.